Skip to Content

Generic Quzyttir Availability

Last updated on Sep 8, 2021.

Quzyttir is a brand name of cetirizine, approved by the FDA in the following formulation(s):

QUZYTTIR (cetirizine hydrochloride - solution;intravenous)

  • Manufacturer: JDP
    Approval date: October 4, 2019
    Strength(s): 10MG/ML (10MG/ML) [RLD]

Has a generic version of Quzyttir been approved?

No. There is currently no therapeutically equivalent version of Quzyttir available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Quzyttir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Non-sedating antihistamine injection formulations and methods of use thereof
    Patent 8,263,581
    Issued: September 11, 2012
    Inventor(s): Du; Jie
    Assignee(s): JDP Therapeutics, Inc.

    Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector.

    Patent expiration dates:

    • February 28, 2030
      ✓ 
      Patent use: TREATMENT OF ACUTE URTICARIA
  • Non-sedating antihistamine injection formulations and methods of use thereof
    Patent 8,314,083
    Issued: November 20, 2012
    Inventor(s): Du; Jie
    Assignee(s): JDP Therapeutics, Inc.

    Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions therewith.

    Patent expiration dates:

    • February 28, 2030
      ✓ 
      Patent use: METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
  • Non-sedating antihistamine injection formulations and methods of use thereof
    Patent 8,513,259
    Issued: August 20, 2013
    Assignee(s): JDP Therapeutics, Inc.

    Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine.

    Patent expiration dates:

    • February 11, 2030
      ✓ 
      Patent use: METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
  • Non-sedating antihistamine injection formulations and methods of use thereof
    Patent 9,119,771
    Issued: September 1, 2015
    Assignee(s): JDP THERAPEUTICS, INC.

    Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector.

    Patent expiration dates:

    • February 11, 2030
      ✓ 
      Patent use: TREATMENT OF ACUTE URTICARIA
  • Non-sedating antihistamine injection formulations and methods of use thereof
    Patent 9,180,090
    Issued: November 10, 2015
    Assignee(s): JDP THERAPEUTICS, INC.

    Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions.

    Patent expiration dates:

    • February 11, 2030
      ✓ 
      Patent use: TREATMENT OF ACUTE URTICARIA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • October 4, 2022 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.